{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tian Y"],"funding":["Medical Research Project of the Innovation Capability Enhancement Plan of Xi’an","Boost Program Research Project of Xijing Hospital","National Natural Science Foundation 579 of China","National Natural Science Foundation of China"],"pagination":["546"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9960671"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(2)"],"pubmed_abstract":["Urologic cancers, particularly kidney, bladder, and prostate cancer, have a growing incidence and account for about a million annual deaths worldwide. Treatments, including surgery, chemotherapy, radiotherapy, hormone therapy, and immunotherapy are the main therapeutic options in urologic cancers. Immunotherapy is now a clinical reality with marked success in solid tumors. Immunological checkpoint blockade, non-specific activation of the immune system, adoptive cell therapy, and tumor vaccine are the main modalities of immunotherapy. Immunotherapy has long been used to treat urologic cancers; however, dose-limiting toxicities and low response rates remain major challenges in the clinic. Herein, nanomaterial-based platforms are utilized as the \"savior\". The combination of nanotechnology wit"],"journal":["Pharmaceutics"],"pubmed_title":["Nanomedicine for Combination Urologic Cancer Immunotherapy."],"pmcid":["PMC9960671"],"funding_grant_id":["21YXYJ0107","No.82173121","31700818","XJZT21L09","82173121"],"pubmed_authors":["Liu Z","Zhu Z","Tian Y","Wang F","Wang X","Wang J","Li L"],"additional_accession":[]},"is_claimable":false,"name":"Nanomedicine for Combination Urologic Cancer Immunotherapy.","description":"Urologic cancers, particularly kidney, bladder, and prostate cancer, have a growing incidence and account for about a million annual deaths worldwide. Treatments, including surgery, chemotherapy, radiotherapy, hormone therapy, and immunotherapy are the main therapeutic options in urologic cancers. Immunotherapy is now a clinical reality with marked success in solid tumors. Immunological checkpoint blockade, non-specific activation of the immune system, adoptive cell therapy, and tumor vaccine are the main modalities of immunotherapy. Immunotherapy has long been used to treat urologic cancers; however, dose-limiting toxicities and low response rates remain major challenges in the clinic. Herein, nanomaterial-based platforms are utilized as the \"savior\". The combination of nanotechnology wit","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-05T07:24:33.04Z","creation":"2025-04-05T07:24:33.04Z"},"accession":"S-EPMC9960671","cross_references":{"pubmed":["36839868"],"doi":["10.3390/pharmaceutics15020546"]}}